Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Boundless Bio Inc. ( (BOLD) ) has shared an announcement.
Boundless Bio announced significant updates to its ecDNA-directed therapy programs and leadership team. The company has decided not to advance its BBI-825 program due to complex treatment landscapes and is focusing resources on BBI-355, with initial clinical data expected in 2025, and the third ecDTx program, aiming for a development candidate by mid-2025. Leadership changes include the departure of CMO Klaus Wagner and CBO Neil Abdollahian, with James L. Freddo stepping in as interim CMO. These strategic decisions extend the company’s operational funding into 2027, demonstrating a commitment to advancing its therapeutic pipeline and addressing unmet oncogene-amplified cancer needs.
More about Boundless Bio Inc.
Boundless Bio is a clinical-stage oncology company focused on developing transformative therapies for oncogene-amplified cancers by targeting extrachromosomal DNA (ecDNA). The company is pioneering ecDNA-directed therapeutic candidates, such as BBI-355 and BBI-825, and operates its Spyglass platform for further program development, headquartered in San Diego, CA.
YTD Price Performance: -76.28%
Average Trading Volume: 79,695
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $75.37M
For detailed information about BOLD stock, go to TipRanks’ Stock Analysis page.
